Clone:
REA1051
Type of antibody:
Primary antibodies, Recombinant antibodies
Isotype:
recombinant human IgG1
Applications:
FC
Alternative names:
NTRKR1

Extended validation for ROR1 Antibody, anti-human, REAfinity™

Specificity

Epitope competition
In order to compare the epitope specificity of an antibody, the clone being used is compared with other known clones recognizing the same antigen in a competition assay.
Other clonesOverlap in epitope recognition with REA1051
2A2++
4A5++
Cells were incubated with an excess of purified unconjugated ROR1 (REA1051) antibody followed by staining with fluorochrome-conjugated antibodies of other known clones against the same marker. Based on the fluorescence signal obtained, the clones were identified as recognizing completely overlapping (++), partially overlapping (+), or completely different epitopes (-) of the marker.

Sensitivity

Performance comparison
Selected fluorochrome conjugated antibodies from Miltenyi Biotec were compared to commercially available hybridoma clones in flow cytometry analysis.
View details
Flow cytometric comparison of different clones for ROR1. A mixtur of human peripheral blood mononuclear cells (PBMCs) and JeKo-1 cells were stained with ROR1 antibodies and with a suitable counterstaining. As a control, ROR1 antibody staining was omitted and cells were measured in the same channels. Flow cytometry was performed with the MACSQuant® Analyzer. Cell debris, dead cells, and cell doublets were excluded from the analysis based on scatter signals and 4',6-diamidino-2-phenylindole (DAPI) fluorescence. No FcR Blocking Reagent was used. The recommended titers of respective antibodies from different suppliers were used.
View details
Flow cytometric comparison of different clones for ROR1. A mixtur of human peripheral blood mononuclear cells (PBMCs) and JeKo-1 cells were stained with ROR1 antibodies and with a suitable counterstaining. As a control, ROR1 antibody staining was omitted and cells were measured in the same channels. Flow cytometry was performed with the MACSQuant® Analyzer. Cell debris, dead cells, and cell doublets were excluded from the analysis based on scatter signals and 4',6-diamidino-2-phenylindole (DAPI) fluorescence. No FcR Blocking Reagent was used. The recommended titers of respective antibodies from different suppliers were used.
View details
Flow cytometric comparison of different clones for ROR1. A mixtur of human peripheral blood mononuclear cells (PBMCs) and JeKo-1 cells were stained with ROR1 antibodies and with a suitable counterstaining. As a control, ROR1 antibody staining was omitted and cells were measured in the same channels. Flow cytometry was performed with the MACSQuant® Analyzer. Cell debris, dead cells, and cell doublets were excluded from the analysis based on scatter signals and 4',6-diamidino-2-phenylindole (DAPI) fluorescence. No FcR Blocking Reagent was used. The recommended titers of respective antibodies from different suppliers were used.
View details
Flow cytometric comparison of different clones for ROR1. A mixtur of human peripheral blood mononuclear cells (PBMCs) and JeKo-1 cells were stained with ROR1 antibodies and with a suitable counterstaining. As a control, ROR1 antibody staining was omitted and cells were measured in the same channels. Flow cytometry was performed with the MACSQuant® Analyzer. Cell debris, dead cells, and cell doublets were excluded from the analysis based on scatter signals and 4',6-diamidino-2-phenylindole (DAPI) fluorescence. No FcR Blocking Reagent was used. The recommended titers of respective antibodies from different suppliers were used.
Flow cytometric comparison of different clones for ROR1. A mixtur of human peripheral blood mononuclear cells (PBMCs) and JeKo-1 cells were stained with ROR1 antibodies and with a suitable counterstaining. As a control, ROR1 antibody staining was omitted and cells were measured in the same channels. Flow cytometry was performed with the MACSQuant® Analyzer. Cell debris, dead cells, and cell doublets were excluded from the analysis based on scatter signals and 4',6-diamidino-2-phenylindole (DAPI) fluorescence. No FcR Blocking Reagent was used. The recommended titers of respective antibodies from different suppliers were used.
Fixation data
To provide an indication on how an antibody performs after fixation of cells, in-house data on staining results before and after fixation with 3.7% formaldehyde using Miltenyi Biotec antibodies are provided. Different experimental settings may lead to different results.
No fixation
Post fixation
View details
Comparison of staining pattern on non-fixed and fixed cells using ROR1 (REA1051). The performance of the antibody after fixation was tested by comparing the staining pattern on fresh (no fixation) versus fixed (post fixation) cells.
View details
Comparison of staining pattern on non-fixed and fixed cells using ROR1 (REA1051). The performance of the antibody after fixation was tested by comparing the staining pattern on fresh (no fixation) versus fixed (post fixation) cells.
Comparison of staining pattern on non-fixed and fixed cells using ROR1 (REA1051). The performance of the antibody after fixation was tested by comparing the staining pattern on fresh (no fixation) versus fixed (post fixation) cells.

Specifications for ROR1 Antibody, anti-human, REAfinity™

Overview

Clone REA1051 recognizes the human ROR1 antigen, also known as receptor tyrosine kinase-like orphan receptor 1. ROR1 has characteristics of an oncofetal gene and was recently identified to be overexpressed at the gene and protein levels in chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL). ROR1 expression has also been detected in ovarian cancer, renal cancer, melanoma, and lung adenocarcinoma, suggesting a general role of ROR1 in cancer genesis and/or maintenance. Moreover, ROR1 expression has been found in undifferentiated embryonic stem cells, in adipose tissue, at early stages of B cell development, but not in major adult tissues. Therefore, ROR1 is a potential therapeutic target and a biomarker to identify and enumerate malignant cells in CLL and MCL blood samples via flow cytometry.
Additional information: Clone REA1051 displays negligible binding to Fc receptors.

Alternative names

NTRKR1

Detailed product information

Technical specifications

CloneREA1051
Clonalitymonoclonal
Isotyperecombinant human IgG1
Isotype controlREA Control Antibody (S), human IgG1
Hostcell line
Type of antibodyPrimary antibodies, Recombinant antibodies
Specieshuman
AntigenROR1
Alternative names of antigenNTRKR1
Molecular mass of antigen [kDa]101
Distribution of antigentumor cells, pre B cells
Entrez Gene ID4919
RRIDAB_2733448, AB_2733449, AB_2733013, AB_2733014, AB_2734053, AB_2734054, AB_2733566, AB_2733567

Resources for ROR1 Antibody, anti-human, REAfinity™

Certificates

Please follow this
link
to search for Certificates of Analysis (CoA) by lot number.

References for ROR1 Antibody, anti-human, REAfinity™

Publications

  1. Fukuda, T. et al. (2008) Antisera induced by infusions of autologous Ad-CD154-leukemia B cells identify ROR1 as an oncofetal antigen and receptor for Wnt5a. Proc. Natl. Acad. Sci. U.S.A. 105: 3047-3052
  2. Hudecek, M. et al. (2010) The B-cell tumor–associated antigen ROR1 can be targeted with T cells modified to express a ROR1-specific chimeric antigen receptor. Blood 116(22): 4532-4541
  3. Yang, J. et al. (2011) Therapeutic potential and challenges of targeting receptor tyrosine kinase ROR1 with monoclonal antibodies in B-cell malignancies. PLoS One 6(6): e21018
  4. Daneshmanesh, A. H. et al. (2012) Monoclonal antibodies against ROR1 induce apoptosis of chronic lymphocytic leukemia (CLL) cells. Leukemia 26(6): 1348-1355
  5. Baskar, S. et al. (2012) Targeting malignant B cells with an immnunotoxin against ROR1. mAbs 4(3): 349-361

Related products for
ROR1 Antibody, anti-human, REAfinity™

3 products available

Seems like you are coming from USA!
Do you want to visit our website in your country?